Metformin

Phase 2/3UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 34/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

HIV/AIDS

Conditions

HIV/AIDS

Trial Timeline

Feb 1, 2019 → Dec 31, 2022

NCT ID

NCT04500678

About Metformin

Metformin is a phase 2/3 stage product being developed by Merck for HIV/AIDS. The current trial status is unknown. This product is registered under clinical trial identifier NCT04500678. Target conditions include HIV/AIDS.

What happened to similar drugs?

3 of 5 similar drugs in HIV/AIDS were approved

Approved (3) Terminated (1) Active (2)

✅TruvadaGilead SciencesApproved

✅bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) + Standard initiation of antiretroviral therapy (ART)Gilead SciencesApproved

✅Emtricitabine and TenofovirGilead SciencesApproved

🔄Biktarvy + SymtuzaGilead SciencesPhase 3

🔄TDF/FTC 300mg/200mg fixed-dose combination tablets + TAF/FTC 25mg/200mg fixed-dose combination tabletsGilead SciencesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04500678	Phase 2/3	UNKNOWN	Feb 1, 2019	Dec 31, 2022	HIV/AIDS
NCT02017561	Phase 2	Completed	Jan 1, 2014	Dec 1, 2019	Metabolic Syndrome X
NCT02710448	Phase 2	Completed	Jun 1, 2012	Oct 1, 2015	Renal Disorder Associated With Type II Diabetes Mellitus
NCT00390273	Phase 1/2	Completed	Dec 1, 2006	Oct 1, 2007	Hyperlactatemia
NCT00134303	Approved	Completed	Jun 1, 2005	Mar 31, 2006	Obesity
NCT00303537	Phase 2/3	UNKNOWN	Nov 1, 2004	Jun 1, 2008	Fatty Liver

Competing Products

11 competing products in HIV/AIDS

See all competitors

Product	Company	Stage	Hype Score
Elvitegravir, Cobicistat, TAF, FTC + Efavirenz, TDF, and 3TC	Gilead Sciences	Pre-clinical	18
Switch to E/C/FTC/TAF daily	Gilead Sciences	Phase 1/2	32
Biktarvy + Symtuza	Gilead Sciences	Phase 3	40
Truvada	Gilead Sciences	Approved	43
bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) + Standard initiation of antiretroviral therapy (ART)	Gilead Sciences	Approved	35
ChAdOx1.HTI + MVA.HTI + GS-9620 + Placebo + Placebo Oral Tablet	Gilead Sciences	Phase 2	35
Emtricitabine and Tenofovir	Gilead Sciences	Approved	39
TDF/FTC 300mg/200mg fixed-dose combination tablets + TAF/FTC 25mg/200mg fixed-dose combination tablets	Gilead Sciences	Phase 3	47
Maraviroc	Pfizer	Phase 1	29
Efavirenz	Bristol Myers Squibb	Pre-clinical	26
Moxifloxacin + Placebo + Efavirenz	Bristol Myers Squibb	Phase 1	29